- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02313064
Oral CXA-10 Study in Healthy Volunteers
A Two-Part, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled and Open-Label Exploratory Food Effect Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49007
- Jasper Clinical Research & Development, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects and female subjects of non-child bearing potential between the ages of 18 and 50 years (inclusive)
- Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and a weight between 60 kg and 100 kg (inclusive)
- In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis. Subjects with blood pressures less than 150/95 mmHg at screening may be enrolled
- Subjects must have resting heart rates (HR) greater than or equal to 50 beats per minute at pre-dose
- QTcF interval (Fredericia's correction factor) must be less than or equal to 430 msec for males and less than or equal to 450 msec for females at screening and pre-dose. Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study. Subjects with a history of congenital long QT syndrome or in the subject's family will be excluded from the study (see Section 6.4)
- Adequate venous access to allow for repeated blood sampling
- Ability to comprehend and comply with procedures
- Agree to commit to participate in the current protocol
- Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)
Exclusion Criteria:
- Female subjects who are pregnant or lactating or who are trying to conceive
- Females must not be of child bearing potential (defined as bilateral oophorectomy, hysterectomy, tubal ligation, or post-menopausal (amenorrhea for minimum of 1 year and post-menopausal status confirmed by follicle stimulating hormone (FSH) testing)). Female subjects unable to bear children (e.g. tubal ligation, hysterectomy, or post-menopausal) must have this documented in the case report form (CRF)
- Female subjects with a positive urine β-human chorionic gonadotropin (β-hCG) test at screening or positive β-hCG urine at pre-dose
- Any clinically relevant abnormality identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
- Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations, personal or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason
- History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
- History of regular alcohol consumption exceeding 14 units/week for women or 21 units/week for men (one unit equal to 125 mL of wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of screening
- History of smoking, including e-cigarettes, or use of nicotine-containing products within 1 month of screening
Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements) within 7 days or 5 half-lives, whichever is longer, prior to dosing and until collection of the final PK sample. Use of any drug including aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior to the first dose and during this study as it will interfere with the pharmacology of CXA-10. Use of high energy supplements or drinks (especially, those containing caffeine, protein supplements, and weight loss drugs) and smoking cessation products (gum, inhalers, patches, e cigarettes) will be prohibited
-Only acetaminophen will be permitted at doses of 2 grams/day
- Sitting blood pressure greater than 150 mmHg systolic and/or greater than 95 mmHg diastolic after 5 minutes rest (feet on floor, arm held at level of heart) at the screening visit
- Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit
- Any abnormalities on 12-lead ECG at screening
- Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)
- A positive urine drug screen for drugs of abuse, including alcohol or positive urine cotinine (greater than or equal to 300 ng/mL for cotinine) at the screening visit or at entry to the clinic (Note: urine cotinine required at screening visit only)
- Treatment with any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs)
- Blood collection of greater than 500 mL within 56 days prior to screening
- Seropositive for human immunodeficiency virus (HIV) at screening
- Positive for Hepatitis B virus surface antigen (HBsAg) or positive Hepatitis C virus antibody (HCV Ab) at screening
- Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CXA-10
single dose of CXA-10 oral formulation
|
Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects.
Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state.
Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
|
Placebo Comparator: CXA-10 placebo
single oral doses of CXA-10 placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with Serious and Non-Serious Adverse Events
Time Frame: First day of dosing through 30 days after the last dose
|
Safety assessments will be performed prior to, during, and after dosing including a visit on Day 18
|
First day of dosing through 30 days after the last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Blok, MD, Jasper Clinic, Michigan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CXA-10-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Injury
-
University of CologneCompletedChronic Renal Failure/ Kidney Disease | Contrast-medium Induced Acute Kidney InjuryGermany
-
Centre Hospitalier Universitaire de NīmesCompletedChronic Kidney Diseases | Acute Kidney InjuryFrance
-
Matthew Harer, MDUnknownNeonatal Acute Kidney Injury | Childhood Chronic Kidney DiseaseUnited States
-
Centre Hospitalier William Morey - Chalon sur SaôneCentre Hospitalier Universitaire DijonRecruitingChronic Kidney Diseases | Acute Kidney Injury | Tomography, Optical CoherenceFrance
-
University of British ColumbiaActive, not recruitingMyocardial Injury | Chronic Kidney Diseases | SurgeryCanada
-
Bangkok Metropolitan Administration Medical College...CompletedChronic Kidney Diseases | Acute Kidney Injury | Contrast Media Toxicity | CurcuminoidThailand
-
Seoul National University HospitalCompletedAcute Kidney Injury | Cardiac Surgery | Chronic Kidney Disease, Stage 5 | Chronic Kidney Disease, Stage 3 | Thoracic Aortic SurgeryKorea, Republic of
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Unity Health TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Mount...UnknownChronic Kidney Disease | Acute Kidney InjuryCanada
-
The Royal Wolverhampton Hospitals NHS TrustCompletedEnd Stage Renal Disease (ESRD) | Chronic Kidney Disease (CKD) | Acute Kidney Injury (AKI) | Estimated Glomerular Filtration Rate (eGFR) | Neutrophil Gelatinase-associated Lipocalin (NGAL) | Serum Creatinine (SCr) | Urine Creatinine (UCr) | Urine Albumin (UAlb)United Kingdom
Clinical Trials on CXA-10
-
Complexa, Inc.Philips Healthcare; Medpace, Inc.; Allegheny Singer Research Institute (also... and other collaboratorsTerminatedPAHUnited States, United Kingdom
-
Complexa, Inc.CompletedAcute Kidney InjuryUnited States
-
Complexa, Inc.Completed
-
Complexa, Inc.Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisUnited States
-
Complexa, Inc.Medpace, Inc.; Allegheny Singer Research Institute (also known as Allegheny... and other collaboratorsTerminated
-
Gladwin, Mark, MDNational Heart, Lung, and Blood Institute (NHLBI); Complexa, Inc.Terminated
-
Sally E. Wenzel MDWithdrawn
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingObesity | AsthmaUnited States
-
Complexa, Inc.CompletedOpen-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney InjuryAcute Kidney Injury (Nontraumatic)United States
-
Cubist Pharmaceuticals LLCCompletedComplicated Urinary Tract InfectionUnited States, Germany, Poland